Europe Central Precocious Puberty (CPP) Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Sep 2020
  • Europe
  • 350 Pages
  • No of Tables: 314
  • No of Figures: 45

Europe Central Precocious Puberty (CPP) Treatment Market, By Type (Medication and Surgery), Month (1-Month, 3-Month, 6-Month and Others), Route of Administration (Parenteral, Implants, Oral and Others), Gender (Girls and Boys), End User (Hospitals, Specialty Clinics, Homecare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe) Industry Trends and Forecast to 2027

Europe Central Precocious Puberty (CPP) Treatment Market Market Analysis and Insights : Europe Central Precocious Puberty (CPP) Treatment Market

Europe central precocious puberty (CPP) treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.3% in the forecast period of 2020 to 2027 and is expected to reach Euro 183.15 million by 2027 from Euro 106.44 million in 2019.

Strategic initiatives by market players and favorable government support for product approval are the major drivers which propelled the demand of the market in the forecast period. Central precocious puberty (CPP) treatment comprises features such presence of novel pipeline drugs will impact in launching new product by the manufactures into the market which enhance its demand as well as high demand of disease specific treatment leads the demand of accurate central precocious puberty (CPP) treatment.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative central precocious puberty (CPP) treatment which is expected to provide various other opportunities in the central precocious puberty (CPP) treatment market. However, adverse effects associated with drug administration and inadequate reimbursement policies expected to restraint the market growth in the forecast period.

The central precocious puberty (CPP) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Central Precocious Puberty (CPP) Treatment Market Europe Central Precocious Puberty (CPP) Treatment Market Scope and Market Size

Central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the central precocious puberty (CPP) treatment market is segmented into medication and surgery. In 2020, medication segment is expected to dominate the market, as most of the children suffering from central precocious puberty rely on medicines, due to fear of invasive surgeries.
  • On the basis of month, the central precocious puberty (CPP) treatment market is segmented into 1-month, 3-month, 6-month and others. In 2020, 1-month segment is dominating in the central precocious puberty (CPP) treatment market as children diagnosed with CPP, prescribed with one month medication to check the adverse effects along with the efficacy of administered GnRH analog.
  • On the basis of route of administration, the central precocious puberty (CPP) treatment market is segmented into parenteral, implants, oral and others. In 2020, parenteral segment is dominating in the central precocious puberty (CPP) treatment market because as medicines administered through parenteral route provides rapid drug response as drug released directly into blood stream.
  • On the basis of gender, the central precocious puberty (CPP) treatment market is segmented into girls and boys. In 2020, girls segment is dominating in the central precocious puberty (CPP) treatment market as central precocious puberty reported to be more common in girls as compared to that of boys.
  • On the basis of end user, the central precocious puberty (CPP) treatment market is segmented into hospitals, specialty clinics, homecare and others. In 2020, hospitals segment is dominating in the central precocious puberty (CPP) treatment market as the advanced diagnostic tools are present at hospitals, moreover number of hospital are increasing which acts as another driving factor for market growth.
  • On the basis of distribution channel, the central precocious puberty (CPP) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies and others. In 2020, direct tender segment is dominating in the market because direct tender provides drugs in bulk for CPP treatment at a reasonable price.

Central Precocious Puberty (CPP) Treatment Market Country Level Analysis

The central precocious puberty (CPP) treatment market is analyzed and market size information is provided by the basis of type, treatment, end user, and distribution channel.

The countries covered in the central precocious puberty (CPP) treatment market report are the Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe.

Europe region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of rising healthcare expenditure. Germany is dominating the European market owing to increasing demand of effective treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Europe Healthcare Expenditure and Strategic Initiatives by Market Players are boosting the Market Growth of Central Precocious Puberty (CPP) Treatment

Central precocious puberty (CPP) treatment market also provides you with detailed market analysis for every country growth in central precocious puberty (CPP) treatment industry with central precocious puberty (CPP) treatment drugs sales, impact of advancement in the central precocious puberty (CPP) treatment technology and changes in regulatory scenarios with their support for the central precocious puberty (CPP) treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Central Precocious Puberty (CPP) Treatment Market Share Analysis

Central precocious puberty (CPP) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Central precocious puberty (CPP) treatment market.

The major companies which are dealing in the central precocious puberty (CPP) treatment are Ipsen Pharma, AbbVie Inc., Mylan N.V., Pfizer Inc., Takeda Pharmaceutical Company Limited, GP Pharm, Debiopharm, AstraZeneca, Sun Pharmaceutical Industries Ltd and Endo International plc, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the central precocious puberty (CPP) treatment market.

For instance,

  • In June 2019, Ipsen Pharma extended its partnership with Debiopharm regarding Decapeptyl (triptorelin) used for CPP treatment to next 15 years. This partnership helped the company to attain a lucrative growth in its overall revenue by maintaining a continued access of its products to paitents.
  • In September 2016, AbbVie Inc. opened up a new manufacturing facility in Singapore so as to accelerate the developmental procedure of various medicines intended for treatment of different kinds of disease. This expansion helped the company to earn more revenue by boosting up the product sales.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the central precocious puberty (CPP) treatment market which also provides the benefit for organization to improve their offering for central precocious puberty (CPP) treatment.

Customization Available: Europe Central Precocious Puberty (CPP) Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY

TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 4 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)

TABLE 5 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 6 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 7 EUROPE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 8 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 9 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 10 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 11 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 12 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 13 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 14 EUROPE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 15 EUROPE SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 16 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)

TABLE 17 EUROPE 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 18 EUROPE 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 19 EUROPE 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 20 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 21 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)

TABLE 22 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 23 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 24 EUROPE ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 25 EUROPE IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 26 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 27 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)

TABLE 28 EUROPE GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 29 EUROPE BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 30 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)

TABLE 31 EUROPE HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 32 EUROPE SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 33 EUROPE HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 34 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 35 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)

TABLE 36 EUROPE DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 37 EUROPE HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 38 EUROPE RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 39 EUROPE ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 40 EUROPE OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)

TABLE 41 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 42 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 43 EUROPE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 44 EUROPE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 45 EUROPE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 46 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 47 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 48 EUROPE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 49 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 50 EUROPE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 51 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 52 EUROPE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 53 EUROPE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 54 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 55 EUROPE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 56 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 57 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 58 EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 59 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 60 GERMANY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 61 GERMANY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 62 GERMANY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 63 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 64 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 65 GERMANY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 66 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 67 GERMANY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 68 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 69 GERMANY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 70 GERMANY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 71 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 72 GERMANY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 73 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 74 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 75 GERMANY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 76 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 77 FRANCE MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 78 FRANCE LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 79 FRANCE ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 80 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 81 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 82 FRANCE LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 83 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 84 FRANCE HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 85 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 86 FRANCE TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 87 FRANCE OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 88 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 89 FRANCE PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 90 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 91 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 92 FRANCE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 93 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 94 U.K. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 95 U.K. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 96 U.K. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 97 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 98 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 99 U.K. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 100 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 101 U.K. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 102 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 103 U.K. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 104 U.K. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 105 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 106 U.K. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 107 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 108 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 109 U.K. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 110 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 111 ITALY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 112 ITALY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 113 ITALY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 114 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 115 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 116 ITALY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 117 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 118 ITALY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 119 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 120 ITALY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 121 ITALY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 122 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 123 ITALY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 124 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 125 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 126 ITALY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 127 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 128 NETHERLANDS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 129 NETHERLANDS LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 130 NETHERLANDS ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 131 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 132 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 133 NETHERLANDS LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 134 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 135 NETHERLANDS HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 136 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 137 NETHERLANDS TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 138 NETHERLANDS OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 139 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 140 NETHERLANDS PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 141 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 142 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 143 NETHERLANDS CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 144 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 145 SPAIN MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 146 SPAIN LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 147 SPAIN ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 148 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 149 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 150 SPAIN LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 151 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 152 SPAIN HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 153 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 154 SPAIN TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 155 SPAIN OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 156 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 157 SPAIN PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 158 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 159 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 160 SPAIN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 161 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 162 RUSSIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 163 RUSSIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 164 RUSSIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 165 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 166 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 167 RUSSIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 168 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 169 RUSSIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 170 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 171 RUSSIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 172 RUSSIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 173 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 174 RUSSIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 175 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 176 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 177 RUSSIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 178 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 179 SWITZERLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 180 SWITZERLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 181 SWITZERLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 182 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 183 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 184 SWITZERLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 185 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 186 SWITZERLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 187 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 188 SWITZERLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 189 SWITZERLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 190 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 191 SWITZERLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 192 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 193 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 194 SWITZERLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 195 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 196 TURKEY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 197 TURKEY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 198 TURKEY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 199 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 200 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 201 TURKEY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 202 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 203 TURKEY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 204 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 205 TURKEY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 206 TURKEY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 207 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 208 TURKEY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 209 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 210 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 211 TURKEY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 212 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 213 AUSTRIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 214 AUSTRIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 215 AUSTRIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 216 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 217 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 218 AUSTRIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 219 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 220 AUSTRIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 221 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 222 AUSTRIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 223 AUSTRIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 224 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 225 AUSTRIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 226 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 227 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 228 AUSTRIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 229 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 230 NORWAY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 231 NORWAY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 232 NORWAY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 233 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 234 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 235 NORWAY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 236 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 237 NORWAY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 238 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 239 NORWAY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 240 NORWAY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 241 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 242 NORWAY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 243 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 244 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 245 NORWAY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 246 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 247 HUNGARY MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 248 HUNGARY LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 249 HUNGARY ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 250 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 251 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 252 HUNGARY LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 253 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 254 HUNGARY HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 255 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 256 HUNGARY TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 257 HUNGARY OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 258 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 259 HUNGARY PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 260 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 261 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 262 HUNGARY CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 263 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 264 LITHUANIA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 265 LITHUANIA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 266 LITHUANIA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 267 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 268 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 269 LITHUANIA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 270 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 271 LITHUANIA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 272 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 273 LITHUANIA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 274 LITHUANIA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 275 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 276 LITHUANIA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 277 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 278 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 279 LITHUANIA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 280 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 281 IRELAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 282 IRELAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 283 IRELAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 284 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 285 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 286 IRELAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 287 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 288 IRELAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 289 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 290 IRELAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 291 IRELAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 292 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 293 IRELAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 294 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 295 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 296 IRELAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 297 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 298 POLAND MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 299 POLAND LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 300 POLAND ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 301 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 302 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 303 POLAND LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 304 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 305 POLAND HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 306 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 307 POLAND TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 308 POLAND OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 309 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 310 POLAND PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 311 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 312 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 313 POLAND CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 314 REST OF EUROPE CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19